Increased BMI, Moderate Drinking Associated With Psoriatic Arthritis Risk
Can reducing weight and drinking reduce the risk for psoriatic arthritis?
Psoriatic Arthritis
High Incidence of Co-Occurring Plaque Psoriasis in Palmoplantar Pustulosis
Patients with palmoplantar pustulosis (PPP) with co-occurring plaque psoriasis have a higher incidence of psoriatic arthritis.
Plasma TNF-α, Adiponectin Levels Influence Risk for Psoriatic Arthritis, Psoriasis
The investigators sought to determine whether TNF-α and adiponectin levels might play a role in differentiating psoriatic arthritis from psoriasis.
Methotrexate More Beneficial in Psoriasis Without Concomitant Arthritis
The investigators sought to compare the efficacy and safety of methotrexate to treat psoriasis in patients with and without psoriatic arthritis.
Axial Disease More Common in Psoriatic Arthritis With Acute Skin Problems
Patients with PsA and severe skin manifestations had earlier onset and axial disease.
Increased Risk for Incident Thyroid Disease in Psoriasis
An endocrinology consultation should be considered in patients with psoriatic disease who present with thyroid symptoms.
Treatment Satisfaction Lacking Among Patients With Psoriasis, Psoriatic Arthritis
Considerable numbers of patients with psoriasis and/or psoriatic arthritis in Denmark, Norway, and Sweden are not receiving optimal therapy, according to results of a Scandinavian survey.
Comorbid Metabolic Syndrome, Psoriatic Arthritis Linked to Reduced Health-Related Quality of Life
Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.
TNFi Treatment Patterns Examined Among Pregnant Women
Using a validated claims-based algorithm, study authors identified pregnancies among women 15-54 years of age from the US Sentinel System between January 1 2004 and September 30 2015.
Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study
The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.
Next post in Psoriasis
